{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:49:08Z","timestamp":1777639748098,"version":"3.51.4"},"reference-count":26,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Postmarketing surveillance (PMS) was conducted evaluating safety and effectiveness of etanercept (ETN; Enbrel<jats:sup>\u00ae<\/jats:sup>) in Japan, following all patients with rheumatoid arthritis (RA) during the conditional approval period of ETN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Registration of patients from 1,334 medical sites was conducted between March 2005 and April 2007. Patients were followed for 24 weeks; data regarding patients\u2019 background, safety, and effectiveness was recorded centrally. Adverse events (AE) and adverse drug reactions (ADR) were coded using the Medical Dictionary for Regulatory Activities. Effectiveness was measured using the Disease Activity Score 28 (DAS28).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Of 14,369 patients registered, data collection and evaluation for 7,091 patients by March 2006 is reported. At least 1 AE was observed for 2,173 patients (30.6%); 60% of AE occurred within 8 weeks of starting ETN. Most frequent AE were injection site reaction (n = 377, 5.3%) and rash (n = 228, 3.2%). Serious AE occurred in 403 patients (5.7%); most frequent were pneumonia (n = 59, 0.8%) and interstitial lung disease (n = 42, 0.6%). Pneumonia was the most common specifically important ADR (n = 102, 1.4%). Mean baseline DAS28 was 6.0, which reduced to 4.4 within 4 weeks, and to 3.9 within 24 weeks. The proportion of patients having good or moderate EULAR response measured by DAS28 was 84.1% at Week 24. Effectiveness rates were more favorable in patients concomitantly using methotrexate. Good or moderate EULAR response rate among patients switched from infliximab was 84.9%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>This extensive observational trial, including all patients with RA in Japan taking ETN, found ETN to be both effective and well tolerated by Japanese patients with RA. Trial registration: clinicaltrials.gov identifier NCT00503503.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.080791","type":"journal-article","created":{"date-parts":[[2009,3,31]],"date-time":"2009-03-31T01:41:58Z","timestamp":1238463718000},"page":"898-906","source":"Crossref","is-referenced-by-count":160,"title":["Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan"],"prefix":"10.3899","volume":"36","author":[{"given":"TAKAO","family":"KOIKE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAYOSHI","family":"HARIGAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHIGEKO","family":"INOKUMA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KAZUHIKO","family":"INOUE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NAOKI","family":"ISHIGURO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JUNNOSUKE","family":"RYU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TSUTOMU","family":"TAKEUCHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOSHIYA","family":"TANAKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HISASHI","family":"YAMANAKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KOICHI","family":"FUJII","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BRUCE","family":"FREUNDLICH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MICHIO","family":"SUZUKAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2009,3,30]]},"reference":[{"key":"2018112909192554000_36.5.898.1","unstructured":"U.S. Food and Drug Administration. MEDWatch Program. [Internet. Accessed February 6, 2009.] Available from: http:\/\/www.fda.gov\/cder\/handbook\/medwatch.htm"},{"key":"2018112909192554000_36.5.898.2","unstructured":"Carleton B Foerster V Warren L Smith MA . Post-marketing pharmaco-surveillance in Canada. Health Canada website. [Internet. Accessed February 6, 2009.] Available from: http:\/\/www.hc-sc.gc.ca\/hcs-sss\/alt_formats\/hpb-dgps\/pdf\/pharma\/ref-can_e.pdf"},{"issue":"Suppl 2","key":"2018112909192554000_36.5.898.3","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1136\/ard.61.suppl_2.ii2","article-title":"Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)","volume":"61","author":"Furst","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2018112909192554000_36.5.898.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh464"},{"key":"2018112909192554000_36.5.898.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.10308"},{"key":"2018112909192554000_36.5.898.6","unstructured":"Innovations Report. Half of patients with active early rheumatoid arthritis achieved clinical remission. Innovations Report website [Internet. Accessed February 6, 2009.] Available from: http:\/\/www.innovationsreport.com\/html\/reports\/medicine_health\/report-95903.html"},{"key":"2018112909192554000_36.5.898.7","unstructured":"Japan College of Rheumatology. Introducing Japan College of Rheumatology (JCR). Japan College of Rheumatology website [Internet. Accessed February 6, 2009.] Available from: http:\/\/www.ryumachi-jp.com\/english\/index.html"},{"key":"2018112909192554000_36.5.898.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"2018112909192554000_36.5.898.9","unstructured":"Northrup Grumman Corporation. MedDRA and the MSSO. Northrup Grumman Corporation website [Internet. Accessed February 6, 2009.] Available from: http:\/\/www.meddramsso.com\/MSSOWeb\/index.htm"},{"key":"2018112909192554000_36.5.898.10","unstructured":"ICH Steering Committee. ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting. Pharmaceuticals and Medical Devices Agency website [Internet. Accessed February 6, 2009.] Available from: http:\/\/www.pmda.go.jp\/ich\/e\/e2a_95_3_20e.pdf"},{"key":"2018112909192554000_36.5.898.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"2018112909192554000_36.5.898.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2018112909192554000_36.5.898.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.10148"},{"key":"2018112909192554000_36.5.898.14","first-page":"1444","article-title":"Care pathways in early rheumatoid arthritis","volume":"52","author":"Bernatsky","year":"2006","journal-title":"Can Fam Physician"},{"key":"2018112909192554000_36.5.898.15","doi-asserted-by":"crossref","unstructured":"Donahue KE Gartlehner G Jonas DE . Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2007:124\u201334.","DOI":"10.7326\/0003-4819-148-2-200801150-00192"},{"key":"2018112909192554000_36.5.898.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043299"},{"key":"2018112909192554000_36.5.898.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.20019"},{"key":"2018112909192554000_36.5.898.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"2018112909192554000_36.5.898.19","doi-asserted-by":"publisher","DOI":"10.1186\/ar1994"},{"key":"2018112909192554000_36.5.898.20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.3110"},{"key":"2018112909192554000_36.5.898.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.06.002"},{"key":"2018112909192554000_36.5.898.22","first-page":"1153","article-title":"Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection","volume":"168","author":"Long","year":"2003","journal-title":"CMAJ"},{"key":"2018112909192554000_36.5.898.23","unstructured":"World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO Report 2007. World Health Organization website. [Internet. Accessed February 6, 2009.] Available from: http:\/\/www.who.int\/tb\/en\/"},{"key":"2018112909192554000_36.5.898.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432201"},{"key":"2018112909192554000_36.5.898.25","first-page":"1845","article-title":"A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing","volume":"20","author":"Jundt","year":"1993","journal-title":"J Rheumatol"},{"key":"2018112909192554000_36.5.898.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.056747"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.080791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T06:04:22Z","timestamp":1558245862000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.080791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,30]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,5,12]]},"published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.3899\/jrheum.080791"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.080791","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,30]]}}}